NCT04869345

Brief Summary

Fibromyalgia syndrome (FMS) is a chronic musculoskeletal condition characterized by widespread pain and tenderness, and often accompanied by impaired physical functioning, depressed mood, as well as deficits in positive affect (PA).Standard behavioral therapies typically focus on minimizing negative thoughts and emotions associated with pain and yield only modest treatment effects. Efforts are therefore needed to develop more effective psychological treatments for chronic pain by identifying new targets for intervention. The objectives of this Stage I randomized pilot trial are to evaluate the feasibility, acceptability, and the impact of a previously developed online positive affect (PA) skills intervention -LARKSPUR (Lessons in Affect Regulation to Keep Stress and Pain UndeR control)-in a sample of Hispanic, non-Hispanic other, and non-Hispanic African American patients with fibromyalgia syndrome (FMS).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
95

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 10, 2021

Completed
23 days until next milestone

First Posted

Study publicly available on registry

May 3, 2021

Completed
3 months until next milestone

Study Start

First participant enrolled

July 27, 2021

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 9, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 9, 2022

Completed
11 months until next milestone

Results Posted

Study results publicly available

May 1, 2023

Completed
Last Updated

May 1, 2023

Status Verified

April 1, 2023

Enrollment Period

11 months

First QC Date

April 10, 2021

Results QC Date

March 7, 2023

Last Update Submit

April 7, 2023

Conditions

Outcome Measures

Primary Outcomes (4)

  • Recruitment as Measured by Rates of Enrollment (Aim 1)

    Percent enrolled of total eligible participants.

    At baseline

  • Retention as Measured by Change in Enrollment

    Percentage enrolled at baseline that completed the post-intervention assessment.

    At baseline; at week 11 (post-intervention)

  • Helpfulness, Satisfaction, and Impact as Assessed by Self-Report Participant Feedback Survey (Aim 1)

    The feedback survey collected two Likert-scale questions asking whether the participant recommends the intervention: (1) "Would you recommend LARKSPUR to a friend?" and (2) "Would you recommend LARKSPUR to someone else with chronic pain?". Both questions were measured on an 11-point scale, with 0=Definitely Not to 10=Definitely Yes. Higher scores indicate better outcomes for both questions. The two items were analyzed separately, not combined.

    At week 11 (post-intervention)

  • Length of Intervention Time as Measured by Number of Weeks to Complete Intervention (Aim 1)

    Length of Intervention time as measured by number of weeks the participant took to complete the LARKSPUR intervention program.

    At week 11 (post-intervention)

Secondary Outcomes (8)

  • Change in FMS Pain as Measured by PROMIS Pain Intensity - Short Form 3a (Aim 2)

    At baseline; at week 11 (post-intervention); at week 16 (1 month post intervention)

  • Change in FMS Pain as Measured by PROMIS Pain Interference - Short Form 6b (Aim 2)

    At baseline; at week 11 (post-intervention); at week 16 (1 month post intervention)

  • Change in Physical Functioning as Measured by PROMIS Physical Functioning Short Form 10a (Aim 2)

    At baseline; at week 11 (post-intervention); at week 16 (1 month post intervention)

  • Change in Physical Functioning as Measured by PROMIS Fatigue - Short Form 6a (Aim 2)

    At baseline; at week 11 (post-intervention); at week 16 (1 month post intervention)

  • Change in Depressive Symptoms as Measured by the Center for Epidemiologic Studies Depression Scale Revised (CESD-R-10) (Aim 2)

    At baseline; at week 11 (post-intervention); at week 16 (1 month post intervention)

  • +3 more secondary outcomes

Other Outcomes (2)

  • Change in Affective Reactivity to Stress as Measured by the Daily Modified Differential Emotions Scale (mDES)

    At baseline, at week 11 (post-intervention); at week 16 (1 month post intervention)

  • Change in Affective Reactivity to Stress as Measured by the Daily Inventory of Stressful Events (DISE)

    At baseline, at week 11 (post-intervention); at week 16 (1 month post intervention)

Study Arms (2)

LARKSPUR intervention

EXPERIMENTAL

Lessons in Affect Regulation to Keep Stress and Pain UndeR control

Behavioral: LARKSPUR

Attention Control Condition

NO INTERVENTION

Daily emotion reporting/no intervention

Interventions

LARKSPURBEHAVIORAL

This intervention used in our prior research consists of skills training exercises designed to increase the frequency of positive affect. The 6 week intervention (5 weeks of content plus one week of home practice) consists of five components: (1) Positive events and gratitude; (2) mindfulness; (3) reappraisal; (4) strength and goals; and(5) acts of kindness. Participants will have up to 8 weeks to complete this intervention.

LARKSPUR intervention

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Access to daily internet
  • ≥ 50 years of age
  • Able to read and understand English
  • Physician diagnosis confirmation of FMS AND/OR Score ≥ 13 on the 6-item, self-report fibromyalgia screening tool
  • Report having pain for at least the last three months

You may not qualify if:

  • Cognitive impairment
  • Current behavioral treatment for pain
  • Enrolled in another pain study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NewYork-Presbyterian - Weill Cornell Medicine

New York, New York, 10065, United States

Location

Related Publications (3)

  • Ong AD, Moskowitz JT, Wethington E, Addington EL, Sanni M, Goktas S, Sluys E, Swong S, Kim P, Reid MC. Lessons in Affect Regulation to Keep Stress and Pain UndeR control (LARKSPUR): Design of a randomized controlled trial to increase positive affect in middle-aged and older adults with fibromyalgia. Contemp Clin Trials. 2022 Sep;120:106880. doi: 10.1016/j.cct.2022.106880. Epub 2022 Aug 11.

    PMID: 35964867BACKGROUND
  • Ong A, Wilcox K, Reid MC, Wethington E, Cintron D, Addington E, Goktas S, Moskowitz J. Targeting Daily Positive Events to Improve Emotional and Functional Well-Being in Adults With Fibromyalgia: Insights From the LARKSPUR Randomized Controlled Trial. J Med Internet Res. 2024 Dec 10;26:e54678. doi: 10.2196/54678.

  • Ong AD, Wilcox KT, Moskowitz JT, Wethington E, Addington EL, Sanni MO, Kim P, Reid MC. Feasibility, Acceptability, and Preliminary Efficacy of a Positive Affect Skills Intervention for Adults With Fibromyalgia. Innov Aging. 2023 Jul 13;7(10):igad070. doi: 10.1093/geroni/igad070. eCollection 2023.

Related Links

MeSH Terms

Conditions

Chronic Pain

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Results Point of Contact

Title
Dr. Anthony Ong
Organization
Cornell University

Study Officials

  • Anthony Ong, PhD

    Cornell University

    PRINCIPAL INVESTIGATOR
  • Cary Reid, MD PhD

    Weill Medical College of Cornell University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 10, 2021

First Posted

May 3, 2021

Study Start

July 27, 2021

Primary Completion

June 9, 2022

Study Completion

June 9, 2022

Last Updated

May 1, 2023

Results First Posted

May 1, 2023

Record last verified: 2023-04

Data Sharing

IPD Sharing
Will share

Reduced, de-identified data sets containing data collected from patients, will be made available for secondary use at the National Archive of Computerized Data on Aging (NACDA), a division of ICPSR at the University of Michigan. NACDA is a repository of survey data on aging that has hundreds of social science research data sets available that are drawn from NIA-funded surveys and data collection efforts. NACDA has established protocols for contributors to reliably de-identify survey participants, regardless of whether they have been assembled as part of national random sample surveys or specialized registry data collection efforts. External users may be asked to provide study aims, variables requested, analytic plans, and targeted journals in their data use requests. They will also be asked to not attempt to re-identify participants, either by merging in administrative, census, medical, or other data, or by using a software program that might re-identify participants.

Shared Documents
STUDY PROTOCOL, ICF
Time Frame
Beginning 9 months and ending 36 months following article publication.
Access Criteria
Investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose.

Locations